WALTHAM, Mass., July 7, 2017 /PRNewswire/ -- Alere Inc.
(NYSE: ALR) (the "Company"), a global leader in rapid diagnostic
tests, today announced that its shareholders have voted to approve
the previously announced amended merger with Abbott. In a final
count of the voting results, approximately 63 million of votes cast
at a special meeting voted in favor of the amended merger,
representing over 72.5% of all outstanding Alere shares as of
the May 31, 2017 record date. The
final vote results will be filed on a Form 8-K with the Securities
and Exchange Commission.
Upon closing of the merger, Alere shareholders will receive
$51 per common share in cash, and
Alere will become a subsidiary of Abbott. The transaction remains
subject to the satisfaction of customary closing conditions,
including applicable regulatory approvals.
About Alere
Alere believes that when diagnosing and
monitoring health conditions, Knowing now matters.™ Alere
delivers reliable and actionable information by providing rapid
diagnostic tests, enhancing clinical and economic healthcare
outcomes globally. Headquartered in Waltham, Mass., Alere focuses on rapid
diagnostics for cardiometabolic disease, infectious disease and
toxicology. For more information on Alere, please visit
www.alere.com.
Cautionary Statement Regarding Forward-Looking
Statements
This communication contains forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended. Readers can identify these statements by
forward-looking words such as "may," "could," "should," "would,"
"intend," "will," "expect," "anticipate," "believe," "estimate,"
"continue" or similar words. A number of important factors could
cause actual results of Alere and its subsidiaries to differ
materially from those indicated by such forward-looking statements.
These factors include, but are not limited to, (i) the risk that
the proposed merger with Abbott may not be completed in a timely
manner or at all; (ii) the possibility that any or all of the
various conditions to the consummation of the merger may not be
satisfied or waived, including the failure to receive any required
regulatory approvals from any applicable governmental entities (or
any conditions, limitations or restrictions placed on such
approvals); (iii) the occurrence of any event, change or other
circumstance that could give rise to the termination of the merger
agreement; (iv) the effect of the announcement or pendency of the
transactions contemplated by the merger agreement on Alere's
ability to retain and hire key personnel, its ability to maintain
relationships with its customers, suppliers and others with whom it
does business, or its operating results and business generally; (v)
risks related to diverting management's attention from Alere's
ongoing business operations; (vi) the risk that stockholder
litigation in connection with the transactions contemplated by the
merger agreement may result in significant costs of defense,
indemnification and liability; and (vii) the risk factors detailed
in Part I, Item 1A, "Risk Factors," of our Annual Report on Form
10-K for the fiscal year ended December 31,
2016 (as filed with the Securities and Exchange Commission
on June 5, 2017) and other risk
factors identified herein or from time to time in our periodic
filings with the SEC. Readers should carefully review
these risk factors, and should not place undue reliance on our
forward-looking statements. These forward-looking statements are
based on information, plans and estimates at the date of this
communication. We undertake no obligation to update any
forward-looking statements to reflect changes in underlying
assumptions or factors, new information, future events or other
changes.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/alere-shareholders-approve-amended-merger-with-abbott-300484767.html
SOURCE Alere Inc.